Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …

The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …

Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …

Shortly after the onset of the COVID-19 pandemic, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has acquired numerous variations in its intracellular proteins to …

Dear Editor, The ongoing SARS-CoV-2 pandemic continues to be a significant threat to
global health. First reported in November 2021, the Omicron variant (B. 1.1. 529) is more …

The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …

SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (M pro) is an
attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical …